Investment Types: Mutual Funds

Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study

This Phase 2 study, also known as the SOAR study, is evaluating the safety and efficacy of fostamatinib in patients with warm antibody AIHA who have previously received at least one treatment for this disease, but did not have a meaningful benefit and are still anemic. The SOAR study utilizes an open-label, Simon two-stage design to evaluate fostamatinib at 150 mg BID (twice daily) in patients with warm antibody AIHA, a disease for which there is no available treatment. Stage 1 of the...

Published on .

11th Annual “Evening Before” Benefitting MPTF

The television industry, from Emmy presenters and nominees, to other TV industry members, helped raise funds to support their industry colleagues and friends who benefit from MPTF’s charitable programs and services such as financial assistance, crisis counseling, care giving support and of course the legendary retirement facility in Woodland Hills that is “home” to television and film veterans alike.  “The health and social service needs of our community continue to grow, especially...

Published on .

Novartis teams up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™ to generate research funding and support for the metastatic breast cancer community

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8162931-novartis-kiss-this-4-mbc-eva-longoria/ The pink ribbon breast cancer movement has been very successful at generating awareness and support for early-stage breast cancer prevention, detection and treatment. Kiss This 4 MBC aims...

Published on .

CO2 Solutions Welcomes Kiverdi as a Partner in the VCQ Project

QUEBEC CITY, Sept. 14, 2017 () – CO2 Solutions Inc. is pleased to announce that Kiverdi Inc. (“Kiverdi”) of Hayward, California, has joined the Valorisation Carbone Québec (“VCQ”) Project as a carbon use partner. CO2 Solutions and Kiverdi will demonstrate carbon capture and utilization (“CCU”) through the deployment of Kiverdi’s proprietary bio-process to convert CO2 into bio-based products alongside CO2 Solutions’ leading-edge enzymatic carbon capture technology at the...

Published on .

Calvin Ayre Foundation to Match Donations to Barbuda Relief Effort

Barbuda was directly in Irma’s path, and its Category 5 mix of 300km/hour winds and heavy rain left a trail of devastation in its wake. Gaston Browne, Prime Minister of Antigua and Barbuda, said 90% of the island’s structures have been destroyed and at least one person has been killed, although that latter figure may rise. It’s hard to imagine, but the worst may be yet to come. A new hurricane, Jose, is forming in the Atlantic and has already attained Category 5 status. Help...

Published on .

View Systems Updates Investors with Current Activities

BALTIMORE, MD – 09/07/2017 (PRESS RELEASE JET) — View Systems, Inc. (OTCBB: VSYM), View is fully reporting and current in its filings and reports to the Security and Exchange Commission.  The company’s next step is to fund its “provisional patented” and manufacture its new line of Concealed Weapons Detectors.  Potential relations and discussions with future partners are being investigated. Additional filings are being prepared. View has achieved proof of a working design...

Published on .

Delphi Announces $750 Million Private Offering of Senior Notes by Its Powertrain Systems Spin-Off Subsidiary, Delphi Jersey Holdings PLC

Upon completion of the separation, DPS intends to use the proceeds from the offering, together with borrowings under a $750 million term loan as part of its credit facilities, to fund operating cash, pay taxes, fees and expenses related to the spin-off, and distribute a dividend to Delphi. Pending completion of the separation, proceeds of the offering will be deposited into escrow for the benefit of the holders of the notes. The Notes are being offered for sale to qualified institutional...

Published on .

TAT Technologies Reports Continued Improvement in Profitability and Revenue Growth in Q2 2017

Key Financial Highlights: Revenues for Q2 2017 were $26.6 million compared with $23.5 million in Q2 2016, a 13.2% growth. Revenues for H1 2017 were $53.6 million compared with $47.2 million in H1 2016, a 13.6% growth. Profitability showed significant improvement, both quarter-over-quarter and first half-over-first half: Adjusted EBITDA for Q2 2017 increased to $2.4 million compared with $1.2 million in Q2 2016, an increase of 100%. Adjusted EBITDA for H1 2017 increased to $5.3 million...

Published on .

Healthcare Laws Authorize Practices That Were Criticized by State Auditor in Recent Hospital Report

Press Release – updated: Aug 10, 2017 17:08 EDT Unionville, MO, August 10, 2017 – Hospital Partners Inc. issued the following statements and information regarding the MO State Auditor’s recent report. As a rural hospital / critical access hospital Putnam County Memorial Hospital is authorized by law to assign and bill for clinical laboratory testing provided at a reference lab. The “non-patient” clinical lab testing is...

Published on .

Levo Therapeutics Announces Completion of Series A Financing

Press Release – updated: Aug 11, 2017 07:00 CDT CHICAGO, IL, August 11, 2017 – Levo Therapeutics, Inc. announced today that it has completed a Series A financing, co-led by Samsara BioCapital and an undisclosed healthcare investment fund.  Levo also announced that it has executed a worldwide license agreement with Ferring Pharmaceuticals to develop intranasal carbetocin for Prader-Willi syndrome (PWS), building on Ferring’s...

Published on .